• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.

作者信息

Qadri S M, Ueno Y

机构信息

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

出版信息

Chemotherapy. 1993 Mar-Apr;39(2):128-31. doi: 10.1159/000239114.

DOI:10.1159/000239114
PMID:8384544
Abstract

The antibacterial activity of PD 131628 was determined by the broth dilution method against 105 clinical isolates of Brucella melitensis. Fifty-two and ninety-nine percent of the isolates were inhibited by 0.06 and 0.12 microgram/ml of this quinolone, respectively. One strain which was resistant to 8 other fluoroquinolones, with a minimum inhibitory concentration (MIC) of > 4.0 micrograms/ml, did not show cross-resistance and had an MIC of 2.0 micrograms/ml. Of the 9 fluoroquinolones tested, PD 131628 was most inhibitory followed by CI-960. All the strains were susceptible to conventional drugs like gentamicin, rifampicin, tetracycline and trimethoprim-sulfamethoxazole, with MICs ranging between 0.12 and 1.0 microgram/ml. PD 131628 did not exhibit in vitro synergy with any of the conventional drugs.

摘要

相似文献

1
Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.
Chemotherapy. 1993 Mar-Apr;39(2):128-31. doi: 10.1159/000239114.
2
Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
Chemotherapy. 1993 Nov-Dec;39(6):386-9. doi: 10.1159/000238981.
3
Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.羊种布鲁氏菌分离株对克林沙星及其他四种新型氟喹诺酮类药物的敏感性
Antimicrob Agents Chemother. 1995 May;39(5):1194-5. doi: 10.1128/AAC.39.5.1194.
4
Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).伤寒沙门氏菌和羊种布鲁氏菌对新型氟喹诺酮类药物鲁氟沙星(MF 934)的敏感性
Chemotherapy. 1993 Sep-Oct;39(5):311-4. doi: 10.1159/000239142.
5
In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.土耳其分离的布鲁氏菌对各种抗菌药物的体外活性。
Infect Dis (Lond). 2015 Jun;47(6):364-9. doi: 10.3109/00365548.2014.988748. Epub 2015 Feb 24.
6
Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.AM-1155与妥舒沙星和氟罗沙星对携带GyrA和ParC喹诺酮耐药性改变的淋病奈瑟菌临床分离株的体外抗菌活性比较。
Chemotherapy. 1997 Jul-Aug;43(4):239-44. doi: 10.1159/000239573.
7
Susceptibility of Brucella melitensis to fluoroquinolones.羊种布鲁氏菌对氟喹诺酮类药物的敏感性。
Drugs Exp Clin Res. 1989;15(10):483-5.
8
In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.替加环素、四环素和氟喹诺酮类药物对羊种布鲁氏菌的体外活性
J Chemother. 2008 Feb;20(1):33-7. doi: 10.1179/joc.2008.20.1.33.
9
Antibacterial activity of azithromycin against Brucella melitensis.阿奇霉素对羊种布鲁氏菌的抗菌活性。
Chemotherapy. 1995 Jul-Aug;41(4):253-6. doi: 10.1159/000239353.
10
Antibacterial activity of lomefloxacin against Brucella melitensis.洛美沙星对羊种布鲁氏菌的抗菌活性。
Diagn Microbiol Infect Dis. 1990 May-Jun;13(3):277-9. doi: 10.1016/0732-8893(90)90074-6.

引用本文的文献

1
Prevalence of Brucella melitensis and Brucella abortus aminoglycoside-resistant isolates: a systematic review and meta-analysis.绵羊附睾和牛型布鲁氏菌氨基糖苷类耐药株的流行率:系统评价和荟萃分析。
Braz J Microbiol. 2024 Mar;55(1):429-439. doi: 10.1007/s42770-023-01233-6. Epub 2024 Jan 16.
2
Determination of Virulence-Associated Genes and Antimicrobial Resistance Profiles in Isolates Recovered from Humans and Animals in Iran Using NGS Technology.利用二代测序技术测定伊朗从人和动物身上分离出的菌株中的毒力相关基因及抗菌药物耐药谱。
Pathogens. 2023 Jan 3;12(1):82. doi: 10.3390/pathogens12010082.
3
Proteomics-based screening and antibiotic resistance assessment of clinical and sub-clinical Brucella species: An evolution of brucellosis infection control.
基于蛋白质组学的临床和亚临床布鲁氏菌属筛选及耐药性评估:布鲁氏菌病感染控制的演变。
PLoS One. 2022 Jan 13;17(1):e0262551. doi: 10.1371/journal.pone.0262551. eCollection 2022.
4
Molecular characterization and antimicrobial susceptibility testing of clinical and non-clinical and isolates from Egypt.埃及临床和非临床分离株的分子特征及抗菌药敏试验
One Health. 2021 Apr 27;13:100255. doi: 10.1016/j.onehlt.2021.100255. eCollection 2021 Dec.
5
Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.喹诺酮类药物治疗人类布鲁氏菌病:微生物学和临床研究证据的批判性综述
Antimicrob Agents Chemother. 2006 Jan;50(1):22-33. doi: 10.1128/AAC.50.1.22-33.2006.
6
In vitro activities of six new fluoroquinolones against Brucella melitensis.六种新型氟喹诺酮类药物对羊种布鲁氏菌的体外活性
Antimicrob Agents Chemother. 1999 Jan;43(1):194-5. doi: 10.1128/AAC.43.1.194.